Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Postoperative Nausea and Vomiting
Conditions
Postoperative Nausea and Vomiting
Trial Timeline
Oct 1, 2007 → Jul 1, 2008
NCT ID
NCT00539721About Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo
Rolapitant Dose 1 + Rolapitant Dose 2 + Rolapitant Dose 3 + Rolapitant Dose 4 + Ondansetron + Placebo is a phase 2 stage product being developed by Merck for Postoperative Nausea and Vomiting. The current trial status is completed. This product is registered under clinical trial identifier NCT00539721. Target conditions include Postoperative Nausea and Vomiting.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00539721 | Phase 2 | Completed |
Competing Products
20 competing products in Postoperative Nausea and Vomiting